(S)-3-(benzyloxycarbonyl)-5-oxo-4-oxazolidineacetic acid | 53623-87-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-(benzyloxycarbonyl)-5-oxo-4-oxazolidineacetic acid
• 英文别名: 4-carboxymethyl-5-oxo-oxazolidine-3-carboxylic acid benzyl ester；N-benzyloxycarbonyl-N-hydroxymethyl-aspartic acid 1-lactone；3-Benzyloxycarbonyl-5-oxo-oxazolidin-4-ylessigsaeure；{3-[(Benzyloxy)carbonyl]-5-oxo-1,3-oxazolidin-4-yl}acetic acid；2-(5-oxo-3-phenylmethoxycarbonyl-1,3-oxazolidin-4-yl)acetic acid
• CAS: 53623-87-3
• 化学式: C₁₃H₁₃NO₆
• mdl: MFCD01014117
• 分子量: 279.249
• InChiKey: XGNNOKSIFRVHHA-UHFFFAOYSA-N

物化性质

• 沸点：
  555.6±45.0 °C(Predicted)
• 密度：
  1.411±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  93.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-3-(benzyloxycarbonyl)-5-oxo-4-oxazolidineacetic acid 生成 N-CBZ-4-甲基-5-氧代噁唑烷
  参考文献：
  名称：

  氨基酸和多肽的还原性自由基脱羧

  摘要：

  由N-保护的α-氨基酸在室温下光解其N-羟基吡啶-2-硫酮酯所产生的自由基被叔丁基硫醇有效地淬灭，得到脱羧酸；在适当保护的天冬氨酸和谷氨酸的侧链羧基上已经进行了类似的反应。

  DOI：

  10.1039/c39840001298
• 作为产物：
  描述：

  聚合甲醛 、 N-CBZ-L-天冬氨酸 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 生成 (S)-3-(benzyloxycarbonyl)-5-oxo-4-oxazolidineacetic acid
  参考文献：
  名称：

  The syntheses of various 1-N-(L-aspart-4-oyl)-glycosylamines and their analogs

  摘要：

  DOI：

  10.1016/s0008-6215(00)82437-4

文献信息

• DNA Methyltransferase inhibitors
  申请人：The Penn State Research Foundation

  公开号：EP1420021A1

  公开（公告）日：2004-05-19

  A compound of the formula or a pharmaceutically acceptable salt thereof, whereinR1, R2, and R3 are the same or different and are independently hydrogen, lower alkyl, aryl or substituted aryl, lower alkoxy, lower alkoxyalkyl, or cycloalkyl or cycloalkyl alkoxy, where each cycloalkyl group has from 3-7 members, where up to two of the cycloalkyl members are optionally hetero atoms selected from oxygen and nitrogen, and where any member of the alkyl, aryl or cycloalkyl group is optionally substituted with halogen, lower alkyl or lower alkoxy, aryl or substituted aryl, and whereR3 can be ribose, deoxyribose or phosphorylated derivatives thereof, whereinR1, R2, and R3 are not all hydrogen and whereinwhen R3 is ribose, deoxyribose or phosphorylated derivatives thereof, one of R1 or R2 is not hydrogen.

  该化合物的结构式为 或其药用可接受盐， 其中R1、R2和R3相同或不同，且独立地为氢、较低烷基、芳基或取代芳基、较低烷氧基、较低烷氧基烷基、环烷基或环烷基烷氧基，其中每个环烷基团具有3-7个成员，其中最多两个环烷基成员可选择为氧和氮，且烷基、芳基或环烷基团的任何成员可选择地取代有卤素、较低烷基或较低烷氧基、芳基或取代芳基，以及 其中R3可以是核糖、脱氧核糖或其磷酸化衍生物， 其中R1、R2和R3不全为氢， 当R3为核糖、脱氧核糖或其磷酸化衍生物时，R1或R2中的一个不是氢。
• Reductive radical decarboxylation of amino-acids and peptides
  作者：Derek H. R. Barton、Yolande Hervé、Pierre Potier、Josiane Thierry

  DOI：10.1039/c39840001298

  日期：——

  Radicals generated from N-protected α-amino-acids by photolysis of their N-hydroxypyridine-2-thione esters at room temperature are efficiently quenched by t-butyl thiol to give decarboxy-acids; comparable reactions have been carried out on the side chain carboxy groups of suitably protected aspartic and glutamic acids.

  由N-保护的α-氨基酸在室温下光解其N-羟基吡啶-2-硫酮酯所产生的自由基被叔丁基硫醇有效地淬灭，得到脱羧酸；在适当保护的天冬氨酸和谷氨酸的侧链羧基上已经进行了类似的反应。
• [EN] 4-SULFONYL-SUBSTITUTED BENZOYLALANINE DERIVATES USEFUL AS KYNURENINE-AMINOTRANSFERASE INHIBITORS<br/>[FR] 4-DÉRIVÉS DE BENZOYLALANINE SUBSTITUÉS PAR SULFONYL UTILES EN TANT QU'INHIBITEURS D'AMINOTRANSFÉRASE KYNURÉNINE
  申请人：PELLICCIARI ROBERTO

  公开号：WO2006013085A1

  公开（公告）日：2006-02-09

  The invention relates to compounds of formula (I), in which R, R' and R' are as defined in the disclosure and the pharmaceutically acceptable esters thereof. The compounds of the invention reduce the synthesis of kynurenic acid thus inhibiting the enzyme kynurenine aminotransferase and can be used for the preparation of medicaments for the treatment of those psychiatric and neurological diseases which benefit from an increase in glutamatergic and/or cholinergic neurotransmission, such as depression, bipolar illness, anxiety, Alzheimer's disease. Furthemore, the compounds of the invention are useful for stimulating attention, memory and other cognitive processes in normal individuals of any age, including children, adolescents and the elderly.

  该发明涉及公式（I）的化合物，其中R、R'和R''如披露中定义，以及其药用可接受的酯。该发明的化合物降低了酮烯酸的合成，从而抑制了酮烯氨基转移酶酶，并可用于制备用于治疗那些受益于谷氨酸能和/或胆碱能神经传导增加的精神病和神经病的药物，如抑郁症、双相情感障碍、焦虑症、阿尔茨海默病。此外，该发明的化合物对于刺激正常个体（包括儿童、青少年和老年人）的注意力、记忆和其他认知过程是有用的。
• PROBE FOR iFRET AND USE THEREOF
  申请人：Chung Sang Jeon

  公开号：US20140242606A1

  公开（公告）日：2014-08-28

  The present invention relates to a probe for iFRET and use thereof. Specifically, the present invention relates to a novel probe for iFRET, a method for preparing the probe for iFRET, a method for searching a target protein-specific binding site or a molecule having the binding site using the probe for iFRET, and a method for imaging the target protein using the probe for iFRET. The probe for iFRET according to the present invention utilizes an amino acid in a protein as a fluorescent donor, unlike the conventional FRET method. Therefore, only one fluorescent material is used, and its emission wavelength is distinct from the intrinsic fluorescence of the protein. Thus, high specificity and sensitivity are ensured, and the quantity, activity and mechanism of various proteins can be analyzed in an easy and accurate manner.

  本发明涉及一种用于iFRET的探针及其使用。具体而言，本发明涉及一种新型iFRET探针、制备iFRET探针的方法、使用iFRET探针搜索靶蛋白特异性结合位点或具有结合位点的分子的方法，以及使用iFRET探针成像靶蛋白的方法。本发明的iFRET探针利用蛋白质中的氨基酸作为荧光给体，而不是传统的FRET方法。因此，仅使用一个荧光材料，其发射波长与蛋白质的内在荧光不同。因此，确保了高度的特异性和灵敏度，并且可以轻松准确地分析各种蛋白质的数量、活性和机制。
• CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP3636807A1

  公开（公告）日：2020-04-15

  The present inventors have found that when screening for cyclic peptide compounds that can specifically bind to a target molecule, the use of a library including cyclic peptide compounds having a long side chain in the cyclic portion can improve the hit rate for cyclic peptide compounds that can specifically bind to the target molecule. Meanwhile, the present inventors have found that tryptophan and tyrosine residues, which have conventionally been used in oral low molecular-weight pharmaceuticals and are amino acid residues having an indole skeleton or a hydroxyphenyl group, are not suitable for peptides intended to attain high membrane permeability.

  本发明人发现，在筛选能与目标分子特异性结合的环肽化合物时，使用包括环状部分具有长侧链的环肽化合物库，可以提高能与目标分子特异性结合的环肽化合物的命中率。同时，本发明者发现色氨酸和酪氨酸残基不适合用于旨在获得高膜渗透性的肽，这两种残基通常用于口服低分子量药物，是具有吲哚骨架或羟基苯基的氨基酸残基。